Status:

RECRUITING

The Safety and Efficacy of Rapamycin on Communicating Hydrocephalus Secondary to Intraventricular Hemorrhage

Lead Sponsor:

Beijing Tiantan Hospital

Conditions:

Communicating Hydrocephalus

Cerebral Intraventricular Hemorrhage

Eligibility:

All Genders

18-70 years

Phase:

PHASE2

Brief Summary

This prospective, multicenter, open-label clinical trial is designed to evaluate the safety and efficacy of rapamycin in the treatment of communicating hydrocephalus secondary to intraventricular hemo...

Detailed Description

Communicating hydrocephalus secondary to intraventricular hemorrhage is a serious neurological disorder with the main clinical manifestations of ventricular dilatation, gait disturbance, cognitive dys...

Eligibility Criteria

Inclusion

  • Patients with ventricular dilatation due to intraventricular hemorrhage who clinically present with any one or more of new gait disturbances, cognitive deficits, and urinary incontinence after remission of intraventricular hemorrhage symptoms, and whose brain imaging shows an Evans index (EI) of ≥0.3
  • Age ≥ 18 years and ≤ 70 years
  • Signed informed consent form

Exclusion

  • Participation in another medical trial
  • Have other disease that may affect the patient's symptoms (including gait disturbance, cognitive impairment, urinary incontinence)
  • Allergy to the investigational drug
  • Reduced liver function (increased INR or alanine transaminase concentrations in plasma elevated more than 1.5 times reference values)
  • Reduced kidney function with GFR \< 50
  • Concomitant treatment with strong CYP3A4/5 inducers or inhibitors, such as diltiazem, ketoconazole, or rifampicin.
  • Active or uncontrolled chronic infection
  • Women who are pregnant or breastfeeding
  • Patients who are bedridden or require urinary catheters for extended periods of time.

Key Trial Info

Start Date :

August 1 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

July 1 2025

Estimated Enrollment :

53 Patients enrolled

Trial Details

Trial ID

NCT06563817

Start Date

August 1 2024

End Date

July 1 2025

Last Update

August 21 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Beijing Tiantan Hospital, Capital Medical University

Beijing, Beijing Municipality, China, 100070

The Safety and Efficacy of Rapamycin on Communicating Hydrocephalus Secondary to Intraventricular Hemorrhage | DecenTrialz